199 related articles for article (PubMed ID: 26861246)
21. Antibiotic synergy testing should not be routine for patients with cystic fibrosis who are infected with multiresistant bacterial organisms.
Aaron SD
Paediatr Respir Rev; 2007 Sep; 8(3):256-61. PubMed ID: 17868924
[TBL] [Abstract][Full Text] [Related]
22. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues.
Waters V; Ratjen F
Expert Rev Anti Infect Ther; 2006 Oct; 4(5):807-19. PubMed ID: 17140357
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics.
Ballmann M; Smyth A; Geller DE
Respir Med; 2011 Dec; 105 Suppl 2():S2-8. PubMed ID: 22208546
[TBL] [Abstract][Full Text] [Related]
24. Comparison of hospital and home intravenous antibiotic therapy in adults with cystic fibrosis.
Esmond G; Butler M; McCormack AM
J Clin Nurs; 2006 Jan; 15(1):52-60. PubMed ID: 16390524
[TBL] [Abstract][Full Text] [Related]
25. Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: a pilot study.
Connett GJ; Pike KC; Legg JP; Cathie K; Dewar A; Foote K; Harris A; Faust SN
Ther Adv Respir Dis; 2015 Dec; 9(6):272-80. PubMed ID: 26341118
[TBL] [Abstract][Full Text] [Related]
26. Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis.
Charrier C; Rodger C; Robertson J; Kowalczuk A; Shand N; Fraser-Pitt D; Mercer D; O'Neil D
Orphanet J Rare Dis; 2014 Nov; 9():189. PubMed ID: 25433388
[TBL] [Abstract][Full Text] [Related]
27. Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure.
Miller C; McMullin B; Ghaffari A; Stenzler A; Pick N; Roscoe D; Ghahary A; Road J; Av-Gay Y
Nitric Oxide; 2009 Feb; 20(1):16-23. PubMed ID: 18789393
[TBL] [Abstract][Full Text] [Related]
28. The cystic fibrosis airway microbiome.
Rabin HR; Surette MG
Curr Opin Pulm Med; 2012 Nov; 18(6):622-7. PubMed ID: 22965275
[TBL] [Abstract][Full Text] [Related]
29. Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis.
Sherrard LJ; Tunney MM; Elborn JS
Lancet; 2014 Aug; 384(9944):703-13. PubMed ID: 25152272
[TBL] [Abstract][Full Text] [Related]
30. Value of inhaled antibiotics in cystic fibrosis patients.
Wunderlich P; Paul KD; Wehner J
Acta Univ Carol Med (Praha); 1990; 36(1-4):34-6. PubMed ID: 2130713
[TBL] [Abstract][Full Text] [Related]
31. [Antibiotic treatment of lung disease in cystic fibrosis].
Biasini GC; Pistocchi E; Miano A
Pediatr Med Chir; 1983; 5(4):157-60. PubMed ID: 6647075
[TBL] [Abstract][Full Text] [Related]
32. Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection.
Martina P; Feliziani S; Juan C; Bettiol M; Gatti B; Yantorno O; Smania AM; Oliver A; Bosch A
Int J Med Microbiol; 2014 Nov; 304(8):1182-91. PubMed ID: 25217078
[TBL] [Abstract][Full Text] [Related]
33. Antibiotic treatment. Aerosol therapy.
Hodson ME
Chest; 1988 Aug; 94(2 Suppl):156S-162S. PubMed ID: 3396438
[TBL] [Abstract][Full Text] [Related]
34. Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum.
Devereux G; Fraser-Pitt D; Robertson J; Devlin E; Mercer D; O'Neil D
EBioMedicine; 2015 Oct; 2(10):1507-12. PubMed ID: 26629546
[TBL] [Abstract][Full Text] [Related]
35. [Continuous intravenous antibiotic home treatment in 11 patients with cystic fibrosis in The Northern Netherlands].
van Aalderen WM; Mannes GP; van Bommel G; Voorthuis I; Bosma E; Heymans HS
Ned Tijdschr Geneeskd; 1993 Nov; 137(48):2482-6. PubMed ID: 8272123
[TBL] [Abstract][Full Text] [Related]
36. Inhaled antibiotics in Cystic Fibrosis (CF) and non-CF bronchiectasis.
Tay GT; Reid DW; Bell SC
Semin Respir Crit Care Med; 2015 Apr; 36(2):267-86. PubMed ID: 25826593
[TBL] [Abstract][Full Text] [Related]
37. Is there a role for antimicrobial stewardship in cystic fibrosis?
Waters VJ; Ratjen FA
Ann Am Thorac Soc; 2014 Sep; 11(7):1116-9. PubMed ID: 25102101
[TBL] [Abstract][Full Text] [Related]
38. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
Shah PI; Bush A; Canny GJ; Colin AA; Fuchs HJ; Geddes DM; Johnson CA; Light MC; Scott SF; Tullis DE
Eur Respir J; 1995 Jun; 8(6):954-8. PubMed ID: 7589382
[TBL] [Abstract][Full Text] [Related]
39. [Etiopathogenic and therapeutic aspects of chronic respiratory infection in cystic fibrosis].
Caramia G; Gagliardini R; Rocchi AL; Palumbo P
Minerva Pediatr; 1986 Jul; 38(13-14):569-78. PubMed ID: 3528799
[No Abstract] [Full Text] [Related]
40. Ofloxacin in cystic fibrosis.
Meyer H
Drugs; 1987; 34 Suppl 1():177-9. PubMed ID: 3481319
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
